Glycort

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Mid 2018 – Recap of Warning Letters, Import Alerts and Non-Compliances

In our mid-2018 compliance review, we look at inspection challenges faced by companies across the w

Emcure’s US CEO ‘looted millions’, fixed prices with Mylan, Teva and others

As 2016 draws to a close, we look at some recent cases of (alleged) drug price-fixing and examines i

Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?

 Over 700 commonly used generic medicines were recommended for suspension by the European Medic